Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Sanofi, a global biopharmaceutical company, announced plans to acquire Blueprint Medicines, a biopharma firm specializing in systemic mastocytosis (SM) and KIT-driven diseases, in a deal valued at approximately $9.5 billion. This acquisition will expand Sanofi's portfolio in rare immunological diseases and add to its early-stage pipeline in immunology.

The agreement includes the acquisition of Ayvakit/Ayvakyt (avapritinib), a leading medicine for advanced and indolent systemic mastocytosis, as well as promising pipeline drugs such as elenestinib and BLU-808. Sanofi will pay $129 per share in cash and offer additional contingent value rights based on future milestones.

This strategic move aims to enhance Sanofi's immunology capabilities and accelerate its transformation into a leading immunology company. The acquisition is expected to be completed by Q3 2025, subject to customary conditions and regulatory approvals.